🚀 VC round data is live in beta, check it out!
Terumo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Terumo and similar public comparables like West Pharma, Straumann Group, Smith & Nephew, Steris and more.
Terumo Overview
About Terumo
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo’s revenue.
Founded
1921
HQ
Employees
30.7K
Website
Sectors
Financials (LTM)
EV
$20B
Terumo Financials
Terumo reported last 12-month revenue of $7B and EBITDA of $2B.
In the same LTM period, Terumo generated $4B in gross profit, $2B in EBITDA, and $847M in net income.
Revenue (LTM)
Terumo P&L
In the most recent fiscal year, Terumo reported revenue of $7B and EBITDA of $2B.
Terumo expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7B | XXX | $7B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $847M | XXX | $802M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Terumo Stock Performance
Terumo has current market cap of $19B, and enterprise value of $20B.
Market Cap Evolution
Terumo's stock price is $12.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20B | $19B | -0.4% | XXX | XXX | XXX | $0.54 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTerumo Valuation Multiples
Terumo trades at 2.9x EV/Revenue multiple, and 11.6x EV/EBITDA.
EV / Revenue (LTM)
Terumo Financial Valuation Multiples
As of March 28, 2026, Terumo has market cap of $19B and EV of $20B.
Equity research analysts estimate Terumo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Terumo has a P/E ratio of 22.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19B | XXX | $19B | XXX | XXX | XXX |
| EV (current) | $20B | XXX | $20B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 11.6x | XXX | 12.0x | XXX | XXX | XXX |
| EV/EBIT | 17.2x | XXX | 18.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | 5.7x | XXX | XXX | XXX |
| P/E | 22.3x | XXX | 23.5x | XXX | XXX | XXX |
| EV/FCF | 36.4x | XXX | 21.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Terumo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Terumo Margins & Growth Rates
Terumo's revenue in the last 12 month grew by 8%.
Terumo's revenue per employee in the last FY averaged $0.2M.
Terumo's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Terumo's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Terumo Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | — | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Terumo Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| West Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Straumann Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Smith & Nephew | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Terumo M&A Activity
Terumo acquired XXX companies to date.
Last acquisition by Terumo was on XXXXXXXX, XXXXX. Terumo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Terumo
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTerumo Investment Activity
Terumo invested in XXX companies to date.
Terumo made its latest investment on XXXXXXXX, XXXXX. Terumo invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Terumo
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Terumo
| When was Terumo founded? | Terumo was founded in 1921. |
| Where is Terumo headquartered? | Terumo is headquartered in Japan. |
| How many employees does Terumo have? | As of today, Terumo has over 30K employees. |
| Who is the CEO of Terumo? | Terumo's CEO is Hikaru Samejima. |
| Is Terumo publicly listed? | Yes, Terumo is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Terumo? | Terumo trades under 4543 ticker. |
| When did Terumo go public? | Terumo went public in 1982. |
| Who are competitors of Terumo? | Terumo main competitors are West Pharma, Straumann Group, Smith & Nephew, Steris. |
| What is the current market cap of Terumo? | Terumo's current market cap is $19B. |
| What is the current revenue of Terumo? | Terumo's last 12 months revenue is $7B. |
| What is the current revenue growth of Terumo? | Terumo revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Terumo? | Current revenue multiple of Terumo is 2.9x. |
| Is Terumo profitable? | Yes, Terumo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Terumo? | Terumo's last 12 months EBITDA is $2B. |
| What is Terumo's EBITDA margin? | Terumo's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Terumo? | Current EBITDA multiple of Terumo is 11.6x. |
| What is the current FCF of Terumo? | Terumo's last 12 months FCF is $546M. |
| What is Terumo's FCF margin? | Terumo's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Terumo? | Current FCF multiple of Terumo is 36.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.